Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Receivables (2016 - 2019)

Theravance Biopharma (TBPH) has disclosed Receivables for 7 consecutive years, with $20.1 million as the latest value for Q3 2019.

  • On a quarterly basis, Receivables rose 189.81% to $20.1 million in Q3 2019 year-over-year; TTM through Sep 2019 was $20.1 million, a 189.81% increase, with the full-year FY2018 number at $6.0 million, down 35.46% from a year prior.
  • Receivables was $20.1 million for Q3 2019 at Theravance Biopharma, roughly flat from $20.1 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $39.1 million in Q1 2016 to a low of $4.8 million in Q1 2018.
  • A 5-year average of $17.1 million and a median of $13.1 million in 2017 define the central range for Receivables.
  • Peak YoY movement for Receivables: soared 674066.67% in 2015, then tumbled 81.96% in 2017.
  • Theravance Biopharma's Receivables stood at $37.2 million in 2015, then plummeted by 73.83% to $9.7 million in 2016, then dropped by 3.7% to $9.4 million in 2017, then tumbled by 35.46% to $6.0 million in 2018, then surged by 232.46% to $20.1 million in 2019.
  • Per Business Quant, the three most recent readings for TBPH's Receivables are $20.1 million (Q3 2019), $20.1 million (Q2 2019), and $7.9 million (Q1 2019).